Back

RHAPSODY: a pivotal phase 3 trial to assess efficacy and safety of rilonacept, an interleukin 1 alpha and beta blocker, in patients with recurrent pericarditis

2 September 2019 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 4 - Cardiovascular epidemiology and trials Trial Design ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Massimo Imazio

University Hospital Santa Maria della Misericordia, Udine (Italy)

11 More presentations in this session

Presentation thumbnail
Professor M. Kavousi (Rotterdam, NL)
Abstract
Presentation thumbnail
Doctor D. Wood (Chapel Hill, US)
Abstract
Presentation thumbnail
Professor D. Brown (Los Angeles, US)
Abstract
Presentation thumbnail
Professor I. Diop (Dakar, SN)
Abstract Slides
Presentation thumbnail
Ms A. Gabet (Saint Maurice, FR)
Abstract

Access the full session

Session thumbnail
Poster Session 4 - Cardiovascular epidemiology and trials

The Event

Event poster

ESC Congress 2019

2 September 2019 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Rilonacept as monotherapy for long-term recurrent pericarditis management: sustained disease control over three years
31 August 2025
thumbnail
Congress Presentation
Interleukin-1 blockade with Anakinra in ST-segment elevation acute myocardial infarction: Results from the VCUART3 study
3 September 2019
thumbnail
Congress Presentation
Genetic analysis of NLRP3 in recurrent pericarditis
27 August 2021
thumbnail
Congress Presentation
Rationale and design of the CADENCE trial: evaluating sotatercept in Cpc-PH secondary to HFpEF
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources